41 results about "Management of Parkinson's disease" patented technology

This invention relates to an implantable device that delivers an effective amounts of red light to the substantia nigra as a treatment for Parkinson's Disease (PD).

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and / or a COMT inhibitor and / or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and / or a COMT inhibitor, and / or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

The invention specifically relates to a pramipexole weekly transdermal patch and a preparation method thereof, belonging to the field of pharmaceutical preparations. The pramipexole weekly transdermal patch comprises three parts: a drug reservoir, an anti-adhesive layer and a backing layer. The invention adopts the hydrophilic substrate mixed penetration enhancer and the lamination pouring method to prepare the double-layer patch, which effectively solves the problem in the preparation of the multi-layer film, and can ensure the constant-speed release of the drug within seven days. Animal experiments show that it is non-irritating and sensitizing to the skin. The patch of the invention has the advantages of clear curative effect, stable quality, good safety and convenient use, and is used for the treatment of Parkinson's disease.

The invention discloses a new pharmaceutical application of schisanhenol and a preparation method of a homogenized suspension of schisanhenol. The homogenized suspension is used for treating Parkinson disease and expanding the application range of schisanhenol, and also provides a potential drug candidate for the treatment of Parkinson disease. A new preparation method is adopted, which is implemented by preparing schisanhenol into a homogenized suspension, and the homogenized suspension is applied to the oral medication of experimental animals. Animal experiments show that in a MPTP induced parkinson rat model, the schisanhenol homogenized suspension can significantly improve the dyskinesia of experimental animals, and shows a good dose-dependent trend. Concrete embodiments are as follows: compared with a model set, the number of falling of a rat taking the schisanhenol homogenized suspension is significantly reduced, and the incubation period is obviously increased; and the climbing time of a rat detected by using a pole climbing method is significantly shortened, and the dyskinesia score is significantly reduced. The schisanhenol homogenized suspension has a good treatment effect on schisanhenol.